Terms: = Germ cell tumor AND ERBB4, MGC138404, 2066, ENSG00000178568, Q15303, p180erbB4, HER4 AND Treatment
43 results:
1. Neuregulin-1 regulates the conversion of M1/M2 microglia phenotype via erbb4-dependent inhibition of the NF-κB pathway.
Ma Y; Fan P; Zhao R; Zhang Y; Wang X; Cui W
Mol Biol Rep; 2022 May; 49(5):3975-3986. PubMed ID: 35166983
[TBL] [Abstract] [Full Text] [Related]
2. RNA-binding protein IGF2BP2 enhances circ_0000745 abundancy and promotes aggressiveness and stemness of ovarian cancer cells via the microRNA-3187-3p/erbb4/PI3K/AKT axis.
Wang S; Li Z; Zhu G; Hong L; Hu C; Wang K; Cui K; Hao C
J Ovarian Res; 2021 Nov; 14(1):154. PubMed ID: 34774079
[TBL] [Abstract] [Full Text] [Related]
3. Circular RNA circ_0001162 promotes cell proliferation and invasion of glioma via the miR-936/erbb4 axis.
Zhou D; Lin X; Wang P; Yang Y; Zheng J; Zhou D
Bioengineered; 2021 Dec; 12(1):2106-2118. PubMed ID: 34057019
[TBL] [Abstract] [Full Text] [Related]
4. The transmembrane protein LRIG1 triggers melanocytic tumor development following chemically induced skin carcinogenesis.
Hoesl C; Fröhlich T; Posch C; Kneitz H; Goebeler M; Schneider MR; Dahlhoff M
Mol Oncol; 2021 Aug; 15(8):2140-2155. PubMed ID: 33786987
[TBL] [Abstract] [Full Text] [Related]
5. Neuregulin 1/erbb4/Akt signaling attenuates cytotoxicity mediated by the APP-CT31 fragment of amyloid precursor protein.
Yoo JY; Kim HB; Baik TK; Lee JH; Woo RS
Exp Mol Pathol; 2021 Jun; 120():104622. PubMed ID: 33684392
[TBL] [Abstract] [Full Text] [Related]
6. Comprehensive genetic analysis of pediatric germ cell tumors identifies potential drug targets.
Kubota Y; Seki M; Kawai T; Isobe T; Yoshida M; Sekiguchi M; Kimura S; Watanabe K; Sato-Otsubo A; Yoshida K; Suzuki H; Kataoka K; Fujii Y; Shiraishi Y; Chiba K; Tanaka H; Hiwatari M; Oka A; Hayashi Y; Miyano S; Ogawa S; Hata K; Tanaka Y; Takita J
Commun Biol; 2020 Sep; 3(1):544. PubMed ID: 32999426
[TBL] [Abstract] [Full Text] [Related]
7. Comparison of genomic landscapes of large cell neuroendocrine carcinoma, small cell lung carcinoma, and large cell carcinoma.
Zhou Z; Zhu L; Niu X; Shen S; Zhao Y; Zhang J; Ye J; Han-Zhang H; Liu J; Liu C; Lu S
Thorac Cancer; 2019 Apr; 10(4):839-847. PubMed ID: 30793508
[TBL] [Abstract] [Full Text] [Related]
8. Lorlatinib treatment Elicits Multiple On- and Off-Target Mechanisms of Resistance in ALK-Driven Cancer.
Redaelli S; Ceccon M; Zappa M; Sharma GG; Mastini C; Mauri M; Nigoghossian M; Massimino L; Cordani N; Farina F; Piazza R; Gambacorti-Passerini C; Mologni L
Cancer Res; 2018 Dec; 78(24):6866-6880. PubMed ID: 30322862
[TBL] [Abstract] [Full Text] [Related]
9. Analysis of copy number loss of the erbb4 receptor tyrosine kinase in glioblastoma.
Jones DC; Scanteianu A; DiStefano M; Bouhaddou M; Birtwistle MR
PLoS One; 2018; 13(1):e0190664. PubMed ID: 29342193
[TBL] [Abstract] [Full Text] [Related]
10. A novel technique of serial biopsy in mouse brain tumour models.
Rogers S; Hii H; Huang J; Ancliffe M; Gottardo NG; Dallas P; Lee S; Endersby R
PLoS One; 2017; 12(4):e0175169. PubMed ID: 28394918
[TBL] [Abstract] [Full Text] [Related]
11. Aberrant expression of ALK and EZH2 in Merkel cell carcinoma.
Veija T; Koljonen V; Bohling T; Kero M; Knuutila S; Sarhadi VK
BMC Cancer; 2017 Mar; 17(1):236. PubMed ID: 28359267
[TBL] [Abstract] [Full Text] [Related]
12. Cervical small cell neuroendocrine tumor mutation profiles via whole exome sequencing.
Cho SY; Choi M; Ban HJ; Lee CH; Park S; Kim H; Kim YS; Lee YS; Lee JY
Oncotarget; 2017 Jan; 8(5):8095-8104. PubMed ID: 28042953
[TBL] [Abstract] [Full Text] [Related]
13. EGFR inhibitors identified as a potential treatment for chordoma in a focused compound screen.
Scheipl S; Barnard M; Cottone L; Jorgensen M; Drewry DH; Zuercher WJ; Turlais F; Ye H; Leite AP; Smith JA; Leithner A; Möller P; Brüderlein S; Guppy N; Amary F; Tirabosco R; Strauss SJ; Pillay N; Flanagan AM
J Pathol; 2016 Jul; 239(3):320-34. PubMed ID: 27102572
[TBL] [Abstract] [Full Text] [Related]
14. Reduced Proteolytic Shedding of Receptor Tyrosine Kinases Is a Post-Translational Mechanism of Kinase Inhibitor Resistance.
Miller MA; Oudin MJ; Sullivan RJ; Wang SJ; Meyer AS; Im H; Frederick DT; Tadros J; Griffith LG; Lee H; Weissleder R; Flaherty KT; Gertler FB; Lauffenburger DA
Cancer Discov; 2016 Apr; 6(4):382-99. PubMed ID: 26984351
[TBL] [Abstract] [Full Text] [Related]
15. Trophoblast subtype-specific EGFR/erbb4 expression correlates with cell cycle progression and hyperplasia in complete hydatidiform moles.
Fock V; Plessl K; Fuchs R; Dekan S; Milla SK; Haider S; Fiala C; Knöfler M; Pollheimer J
Hum Reprod; 2015 Apr; 30(4):789-99. PubMed ID: 25740878
[TBL] [Abstract] [Full Text] [Related]
16. The genetic basis of new treatment modalities in melanoma.
Kunz M
Curr Drug Targets; 2015; 16(3):233-48. PubMed ID: 25654738
[TBL] [Abstract] [Full Text] [Related]
17. Review of our experience with neuroblastoma and ganglioneuroblastoma in adults.
Jrebi NY; Iqbal CW; Joliat GR; Sebo TJ; Farley DR
World J Surg; 2014 Nov; 38(11):2871-4. PubMed ID: 25002244
[TBL] [Abstract] [Full Text] [Related]
18. A prognostic analysis of pediatrics central nervous system small cell tumors: evaluation of EGFR family gene amplification and overexpression.
Liu W; Zhang S; Zhang L; Cui Q; Wang J; Gui T; Pang Q
Diagn Pathol; 2014 Jul; 9():132. PubMed ID: 24986561
[TBL] [Abstract] [Full Text] [Related]
19. Pan-erbB inhibition potentiates BRAF inhibitors for melanoma treatment.
Ng YK; Lee JY; Supko KM; Khan A; Torres SM; Berwick M; Ho J; Kirkwood JM; Siegfried JM; Stabile LP
Melanoma Res; 2014 Jun; 24(3):207-18. PubMed ID: 24709886
[TBL] [Abstract] [Full Text] [Related]
20. Oncogenes in melanoma: an update.
Kunz M
Eur J Cell Biol; 2014; 93(1-2):1-10. PubMed ID: 24468268
[TBL] [Abstract] [Full Text] [Related]
[Next]
